Form 4: Pacira CEO Frank Lee Reports Routine Stock Transaction

Pacira BioSciences CEO Frank D. Lee reported a disposition of 9,272 shares of common stock to cover tax obligations related to a restricted stock unit award.

Summary

• Frank D. Lee, Chief Executive Officer and Director of Pacira BioSciences, Inc. (PCRX), reported a transaction on January 2, 2026.
• The transaction involved the disposition of 9,272 shares of common stock at a price of $24.46 per share.
• These shares were withheld by the issuer to cover tax withholding obligations upon the vesting of a restricted stock unit award.
• Following this transaction, Frank D. Lee beneficially owns 440,500.841 shares of Pacira BioSciences common stock.
• The reported beneficial ownership includes 1,363.841 shares of common stock acquired under the issuer's employee stock purchase plan in June 2025.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction related to executive compensation and tax obligations, which is neutral in sentiment. It does not indicate any significant positive or negative operational or financial developments for the company.

Positives

• The reporting person acquired 1,363.841 shares of common stock under the issuer's employee stock purchase plan in June 2025, indicating continued investment in the company.

Negatives

• The disposition of 9,272 shares represents a reduction in direct beneficial ownership, though it is for a routine tax obligation.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide information relevant to broader industry trends or competitive landscape.

Related Party Transactions

• The transaction involves the disposition of shares by the CEO to the issuer to cover tax obligations related to a restricted stock unit award, which is a standard compensation-related dealing between an executive and their company.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary transaction for tax purposes and does not reflect a change in management's confidence or a significant shift in ownership.

Key Dates

Keywords

Pacira BioSciences, PCRX, Frank D. Lee, Insider Transaction, Form 4, Restricted Stock Units, Tax Withholding, Employee Stock Purchase Plan